Comparing Landauer (LDR) & DexCom (DXCM)

Landauer (NYSE: LDR) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a breakdown of recent ratings for Landauer and DexCom, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Landauer 0 1 0 0 2.00
DexCom 1 6 13 0 2.60

DexCom has a consensus target price of $65.97, indicating a potential upside of 2.93%. Given DexCom’s stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Landauer.


This table compares Landauer and DexCom’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Landauer 16.55% 96.20% 13.62%
DexCom -6.99% -13.99% -6.67%


Landauer pays an annual dividend of $1.10 per share and has a dividend yield of 1.6%. DexCom does not pay a dividend. Landauer pays out 57.3% of its earnings in the form of a dividend.

Risk & Volatility

Landauer has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, DexCom has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.

Valuation and Earnings

This table compares Landauer and DexCom’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Landauer N/A N/A N/A $1.92 35.00
DexCom $718.50 million 7.76 -$50.20 million $0.63 101.73

Landauer has higher earnings, but lower revenue than DexCom. Landauer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

79.6% of Landauer shares are owned by institutional investors. 6.6% of Landauer shares are owned by insiders. Comparatively, 1.7% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Landauer beats DexCom on 8 of the 14 factors compared between the two stocks.

Landauer Company Profile

Landauer, Inc. is a provider of technical and analytical services to determine occupational and environmental radiation exposure. The Company is a provider of outsourced medical physics services, and a provider of radiology related medical products. The Company operates through three segments: Radiation Measurement, Medical Physics and Medical Products. The Company provides radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries. Medical physics services are provided through the Company’s Landauer Medical Physics (LMP) division. The Company uses LMP as a platform to expand into the medical physics services market, serving domestic hospitals, radiation therapy centers and imaging centers. The Company’s Medical Products segment provides medical consumable accessories used in radiology, radiation therapy and image guided surgery procedures.

DexCom Company Profile

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company’s markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Receive News & Ratings for Landauer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landauer and related companies with's FREE daily email newsletter.

Leave a Reply